Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31164697 | 0.86 | GRAMD1A (0.50) | GRAMD1AGCKADORA1MAPT | |
| SCHEMBL15880606 | 0.81 | GRAMD1A (0.48) | GRAMD1AGCKADORA1MAPT | |
| SCHEMBL12199715 | 0.79 | GRAMD1A (0.46) | GRAMD1AGCKADORA1MAPT | |
| SCHEMBL12199718 | 0.79 | GRAMD1A (0.51) | GRAMD1AGCKADORA1MAPT | |
| SCHEMBL166201 | 0.78 | GCK (0.45) | GRAMD1AGCKADORA1OPRM1OPRD1 | |
| SCHEMBL31748905 | 0.78 | GRM5 (0.42) | GRAMD1AGCKADORA1MAPT | |
| SCHEMBL30717625 | 0.76 | GRAMD1A (0.44) | GRAMD1AGCKADORA1MAPT | |
| SCHEMBL30717561 | 0.76 | GRAMD1A (0.43) | GRAMD1AGCKADORA1MAPT | |
| SCHEMBL31164700 | 0.75 | GRAMD1A (0.50) | GRAMD1AGCKADORA1MAPTSCN4A | |
| SCHEMBL30717629 | 0.75 | GCK (0.43) | GRAMD1AGCKADORA1MAPTSCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245267-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING PLOUGH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245267-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING PLOUGH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245267-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GID4, IL5 | GRAMD1A 2410/4885GCK 112/4885ADORA1 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.